{
  "doc_type": "msa",
  "party_a_name": "EKR Therapeutics, Inc.",
  "party_b_name": "EKR Therapeutics, Inc.",
  "effective_date": null,
  "term_length": null,
  "governing_law": "New York",
  "termination_notice_days": null,
  "liability_cap": "[**] US Dollars ($[**])",
  "non_solicit_clause_present": false,
  "data_transfer_outside_uk_eu": "unknown",
  "risk_level": "high",
  "risk_explanation": "governing law appears outside the UK/EU.",
  "_meta": {
    "pdf": "C:\\Users\\sohai\\contractFlow\\data\\raw_pdfs\\cuad_009_pacira_pharmaceuticals_inc_a_r_strategic.pdf",
    "model": "gpt-5.2",
    "mode": "field_agents",
    "input_tokens": 19859,
    "output_tokens": 2321,
    "validate": true,
    "strict": false,
    "coerce": true,
    "structured_outputs": true,
    "issues": [
      "risk_level overridden by deterministic rules (was 'medium')",
      "risk_explanation overridden by deterministic rules"
    ],
    "retrieval": {
      "enabled": true,
      "mode": "field_agents",
      "backend": "bm25",
      "model": null,
      "cache_path": null,
      "cache_hit": null,
      "top_k": 3,
      "max_chunk_chars": 1200,
      "chunk_max_chars": 2000,
      "use_ocr": false,
      "total_chunks": 240,
      "fields": {
        "doc_type": {
          "confidence": 0.62,
          "evidence": [
            {
              "page_num": 42,
              "heading": "10.6 (\"Insurance\")), Article 11 (\"Confidentiality, Press Releases and Publications\"),",
              "snippet": "10.6 (\"Insurance\")), Article 11 (\"Confidentiality, Press Releases and Publications\"),"
            },
            {
              "page_num": 37,
              "heading": null,
              "snippet": "11.3 Duration. The confidentiality and non-use obligations contained in this Agreement shall continue for the duration of this Agreement and for a period of [**] ([**]) years after termination"
            }
          ],
          "attempts": 1,
          "issues": [],
          "prompt_tokens": 858,
          "completion_tokens": 132
        },
        "party_a_name": {
          "confidence": 0.42,
          "evidence": [
            {
              "page_num": 61,
              "heading": "By:     Print Name:     Title:",
              "snippet": "EKR Therapeutics, Inc."
            }
          ],
          "attempts": 2,
          "issues": [],
          "prompt_tokens": 934,
          "completion_tokens": 145
        },
        "party_b_name": {
          "confidence": 0.62,
          "evidence": [
            {
              "page_num": 61,
              "heading": "By:     Print Name:     Title:",
              "snippet": "EKR Therapeutics, Inc."
            }
          ],
          "attempts": 2,
          "issues": [],
          "prompt_tokens": 934,
          "completion_tokens": 145
        },
        "effective_date": {
          "confidence": 0.22,
          "evidence": [
            {
              "page_num": 1,
              "heading": "MARKETING AGREEMENT",
              "snippet": "...is made on October 15, 2009 (the \"Agreement Date\") and is effective as of the Effective Date (as defined below)..."
            }
          ],
          "attempts": 1,
          "issues": [],
          "prompt_tokens": 2142,
          "completion_tokens": 144
        },
        "term_length": {
          "confidence": 0.18,
          "evidence": [
            {
              "page_num": 8,
              "heading": null,
              "snippet": "\"Term\"   Means the term of this Agreement as set out in Section 15;"
            },
            {
              "page_num": 39,
              "heading": "14.4 Non Participation. Should in accordance with Section 14.2, PPI decide not to",
              "snippet": "As used herein \"Term\" refers to the Initial Term and any renewal terms."
            }
          ],
          "attempts": 2,
          "issues": [],
          "prompt_tokens": 1827,
          "completion_tokens": 180
        },
        "governing_law": {
          "confidence": 0.98,
          "evidence": [
            {
              "page_num": 63,
              "heading": null,
              "snippet": "This Note shall be governed by and construed in accordance with the laws of the State of New York"
            },
            {
              "page_num": 49,
              "heading": "21.10 Cumulative Rights. The rights and remedies of each of the Parties under or pursuant",
              "snippet": "21.13 Governing Law. This Agreement and the relationship between the Parties shall be governed by, and interpreted in accordance with New York law"
            }
          ],
          "attempts": 1,
          "issues": [],
          "prompt_tokens": 676,
          "completion_tokens": 119
        },
        "termination_notice_days": {
          "confidence": 0.32,
          "evidence": [
            {
              "page_num": 42,
              "heading": null,
              "snippet": "EKR may terminate this Agreement for convenience at any time upon [**] ([**]) days prior, written notice to PPI."
            }
          ],
          "attempts": 1,
          "issues": [],
          "prompt_tokens": 2344,
          "completion_tokens": 134
        },
        "liability_cap": {
          "confidence": 0.62,
          "evidence": [
            {
              "page_num": 35,
              "heading": "10.8 PPI Liability Limitation. Any and all liability of PPI to EKR howsoever arising in",
              "snippet": "Any and all liability of PPI to EKR howsoever arising... shall be limited ... to [**] US Dollars ($[**]);"
            },
            {
              "page_num": 36,
              "heading": "7.2.12 of  the Supply Agreement.   10.9 EKR Liability Limitation. Any and all liability of",
              "snippet": "Any and all liability of EKR to PPI howsoever arising... shall be limited ... to [**] US Dollars ($[**]);"
            }
          ],
          "attempts": 1,
          "issues": [],
          "prompt_tokens": 1000,
          "completion_tokens": 163
        },
        "non_solicit_clause_present": {
          "confidence": 0.18,
          "evidence": [
            {
              "page_num": 37,
              "heading": null,
              "snippet": "11.3 Duration. The confidentiality and non-use obligations contained in this Agreement shall continue for the duration of this Agreement and for a period of [**] ([**]) years after termination"
            }
          ],
          "attempts": 1,
          "issues": [],
          "prompt_tokens": 2121,
          "completion_tokens": 231
        },
        "data_transfer_outside_uk_eu": {
          "confidence": 0.22,
          "evidence": [
            {
              "page_num": 3,
              "heading": "Confidential Information",
              "snippet": "Means all confidential information, data and materials in whatever form disclosed by or on behalf of one Party  or its Affiliates to the other Party or its Affiliates"
            },
            {
              "page_num": 17,
              "heading": null,
              "snippet": "The cost of submitting any data generated by any Phase IV studies conducted by EKR which is required to be filed with the FDA shall be borne by EKR"
            }
          ],
          "attempts": 2,
          "issues": [],
          "prompt_tokens": 1436,
          "completion_tokens": 238
        },
        "risk_level": {
          "confidence": 0.32,
          "evidence": [
            {
              "page_num": 35,
              "heading": "10.5 Settlement of Claims. The indemnified Party shall not admit liability in respect of,",
              "snippet": "10.6 Insurance. Each Party shall maintain, at its own cost, comprehensive product liability insurance, general commercial liability insurance and business interruption insurance..."
            },
            {
              "page_num": 16,
              "heading": null,
              "snippet": "During the Lease Term, PPI shall: (i) assume the risk of loss or damage to the Transferred Equipment; ... (v) maintain property damage and liability insurance..."
            }
          ],
          "attempts": 1,
          "issues": [],
          "prompt_tokens": 2954,
          "completion_tokens": 220,
          "derived": true,
          "derived_reason": "deterministic risk rules"
        },
        "risk_explanation": {
          "confidence": 0.62,
          "evidence": [
            {
              "page_num": 16,
              "heading": null,
              "snippet": "During the Lease Term, PPI shall: (i) assume the risk of loss or damage to the Transferred Equipment; ... (v) maintain property damage and liability insurance and insurance against loss or damage"
            },
            {
              "page_num": 16,
              "heading": null,
              "snippet": "If any of the Transferred Equipment is lost, stolen, destroyed, damaged beyond repair... PPI shall promptly... pay to EKR an amount equal to the estimated in-place, fair market value"
            },
            {
              "page_num": 45,
              "heading": "18.2 Duration. If such Force Majeure continues unabated for a period of at least ninety",
              "snippet": "If the affected Party is prevented... from performing... for a continuous period of six (6) months the other Party may terminate this Agreement."
            }
          ],
          "attempts": 2,
          "issues": [],
          "prompt_tokens": 2633,
          "completion_tokens": 470,
          "derived": true,
          "derived_reason": "deterministic risk rules"
        }
      },
      "coverage": {
        "fields_total": 10,
        "fields_with_evidence": 10,
        "fields_without_evidence": [],
        "evidence_ratio": 1.0,
        "evidence_snippets_total": 15,
        "unique_evidence_pages": 12,
        "avg_confidence": 0.438,
        "min_confidence": 0.18
      }
    }
  }
}
